LYEL stock forecast, quote, news & analysis
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors... Show more
Lyell Immunopharma (LYEL) Stock Analysis: Pivotal CAR T-Cell Data and Cash Runway in Focus
Key Takeaways
- Lyell Immunopharma (LYEL) traded near $9.9 in mid-October, down roughly 9.8% from the $11.01 closing level recorded about a month earlier.
- As a pre-revenue, clinical-stage biotech, the stock's valuation is driven primarily by clinical progress and cash position rather than earnings.
- Lead candidate ronde-cel is advancing through the pivotal PiNACLE trial in relapsed/refractory large B-cell lymphoma (LBCL).
- The company reported cash, cash equivalents, and marketable securities of about $261 million at the end of Q1 2026, with runway into the third quarter of 2027.
- Additional third-line-plus (3L+) data and Phase 1 data for LYL273 are expected in the second half of 2026.
Current Market Snapshot
Lyell Immunopharma shares have exhibited notable volatility in recent months. After trading in the mid-to-high teens during late summer, the stock pulled back through September and settled near $9.9 by mid-October. Over the trailing 30-day period, the shares declined roughly 9.8%, reflecting a broader pullback in clinical-stage biotechnology names as investors reassess risk appetite in a capital-intensive, pre-revenue segment of the market.
Within the cell therapy sector, sentiment has been mixed as investors weigh promising but still-unproven next-generation CAR T-cell platforms against the long timelines and binary outcomes inherent to oncology development. Lyell's positioning in both hematologic malignancies and solid tumors gives it a differentiated pipeline, but its valuation remains sensitive to clinical data readouts and financing dynamics.
Lyell Immunopharma (LYEL) Business Overview and Competitive Position
Lyell Immunopharma is a late-stage clinical company headquartered in South San Francisco that develops next-generation chimeric antigen receptor (CAR) T-cell therapies for cancer. The company's technology platform is designed to enhance CAR T cells so they resist exhaustion, retain durable stemness, and function effectively in the hostile tumor microenvironment.
Its lead asset, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CD19/CD20 CAR T-cell therapy in pivotal development for patients with relapsed/refractory large B-cell lymphoma. Ronde-cel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration. Lyell is also advancing LYL273, a GCC-targeted CAR T-cell candidate for metastatic colorectal cancer (mCRC), which holds Fast Track designation. The company's proprietary LyFE Manufacturing Center is designed to support commercial-scale production of more than 1,200 CAR T-cell doses per year, a meaningful competitive consideration in a field where manufacturing complexity is a key constraint.
Recent Developments Driving LYEL
Several corporate and clinical milestones have shaped investor sentiment. In March 2026, Lyell closed an additional $50 million tranche of its equity private placement following the achievement of a clinical milestone in the PiNACLE trial, and appointed Smital Shah as Chief Financial and Business Officer.
First-quarter 2026 results showed a narrowing net loss of $24.2 million, down from $52.2 million in the prior-year period, alongside reduced operating expenses and a cash position of approximately $261 million. Management indicated the balance sheet is sufficient to fund operations into the third quarter of 2027.
On the clinical front, data from patients treated with ronde-cel receiving dexamethasone prophylaxis showed no events of Grade 3 or higher cytokine release syndrome and a 4% rate of Grade 3 or higher immune effector cell-associated neurotoxicity syndrome. Separately, LYL273 reported a 67% best overall response rate and an 8-month median progression-free survival at the highest dose level tested in refractory mCRC. Despite these advancements, the stock pulled back through September, consistent with broader volatility across clinical-stage biotech rather than any single disclosed company-specific catalyst.
Trending AI Robots
For traders seeking a more systematic approach to market analysis, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing automated strategies. Tickeron hosts hundreds of AI trading bots that trade thousands of tickers, but only the most relevant and highest-performing bots are featured in this section. These bots vary in trading strategy, timeframe, and performance metrics, giving users the ability to evaluate different approaches side by side. Exploring the page can help investors identify tools aligned with their own risk tolerance and trading style.
2026 Outlook and What Investors Should Watch
Lyell's near-term trajectory hinges on several discrete, verifiable catalysts. Additional data from the expanded 3L+ cohort of the pivotal PiNACLE trial is expected in the second half of 2026, with pivotal data anticipated by mid-2027 and a potential Biologics License Application filing to follow. Phase 1 data for LYL273 in metastatic colorectal cancer is also expected in the second half of 2026 and will help inform the recommended Phase 2 dose.
Investors should also monitor enrollment and readouts from the randomized PiNACLE-H2H Phase 3 trial, which compares ronde-cel against standard-of-care therapies, as well as the company's ability to maintain its cash runway into the third quarter of 2027. As with all clinical-stage oncology companies, key risks include the possibility of adverse safety signals, enrollment delays, regulatory setbacks, and the need for additional capital. These factors, rather than near-term revenue performance, are likely to be the primary drivers of the stock's valuation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for LYEL turns positive, indicating new upward trend
LYEL saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 80 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LYEL's RSI Oscillator exited the oversold zone, 26 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for LYEL just turned positive on October 15, 2026. Looking at past instances where LYEL's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Following a +19.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where LYEL advanced for three days, in 201 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
LYEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for LYEL entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. LYEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.983) is normal, around the industry mean (2.988). P/E Ratio (-0.739) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. LYEL's P/S Ratio (10000.000) is very high in comparison to the industry average of (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology